Development and Validation of a Quantitative Determination Method for the Antitubercular Drug PBTZ169 in Biological Media
- Authors: Stepanova E.S.1, Barsegyan S.S.1, Makarenkova L.M.1, Chistyakov V.V.1
- 
							Affiliations: 
							- People’s Friendship University of Russia, Common Use Center
 
- Issue: Vol 52, No 3 (2018)
- Pages: 248-253
- Section: Article
- URL: https://ogarev-online.ru/0091-150X/article/view/245106
- DOI: https://doi.org/10.1007/s11094-018-1801-x
- ID: 245106
Cite item
Abstract
An HPLC-MS/MS method for quantitative determination of the new antituberculosis drug PBTZ169 in blood serum, urine, and feces using perindopril as an internal standard was developed and validated. The method was selective, specific, accurate, and precise. Calibration curves were linear in the ranges 2 – 2,000, 5 – 3,000, and 100 – 10,000 ng/mL for blood serum, urine, and feces, respectively, with correlation coefficients >0.99. The detection limits of PBTZ169 were 1, 2.5, and 50 ng/mL for serum, urine, and feces, respectively. The limits of quantitation were 2 ng/mL in serum; 5, urine; and 100, feces.
Keywords
About the authors
E. S. Stepanova
People’s Friendship University of Russia, Common Use Center
							Author for correspondence.
							Email: stepanova25@inbox.ru
				                					                																			                												                	Russian Federation, 							Moscow, 117198						
S. S. Barsegyan
People’s Friendship University of Russia, Common Use Center
														Email: stepanova25@inbox.ru
				                					                																			                												                	Russian Federation, 							Moscow, 117198						
L. M. Makarenkova
People’s Friendship University of Russia, Common Use Center
														Email: stepanova25@inbox.ru
				                					                																			                												                	Russian Federation, 							Moscow, 117198						
V. V. Chistyakov
People’s Friendship University of Russia, Common Use Center
														Email: stepanova25@inbox.ru
				                					                																			                												                	Russian Federation, 							Moscow, 117198						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					